Maturity-onset diabetes of the young

Signs and symptoms

MODY accounts for at least 1-5% of all diagnoses of diabetes mellitus, though 50-90% of cases are estimated to be misdiagnosed as type 1, or type 2 diabetes. Estimated prevalence rates indicate 1 per 10,000 in adults, and 1 per 23,000 in children. 50% of first-degree relatives will inherit the same mutation, giving them a greater than 95% lifetime risk of developing MODY themselves. For this reason, correct diagnosis of this condition is important. Typically patients present with a strong family history of diabetes (i.e.: presence of diabetes before the age of 25 in two consecutive generations).

There are two general types of clinical presentation.

• Some forms of MODY produce significant hyperglycemia and the typical signs and symptoms of diabetes: increased thirst and urination (polydipsia and polyuria).
• In contrast, many people with MODY have no signs or symptoms and are diagnosed either by accident, when a high glucose is discovered during testing for other reasons, or screening of relatives of a person discovered to have diabetes. Discovery of mild hyperglycemia during a routine glucose tolerance test for pregnancy is particularly characteristic.

While the goals of diabetes management are the same no matter what type, there are two primary advantages of confirming a diagnosis of MODY.

• Insulin may not be necessary and it may be possible to switch a person from insulin injections to oral agents without loss of glycemic control.
• It may prompt screening of relatives and so help identify other cases in family members.

As it occurs infrequently, many cases of MODY are initially assumed to be more common forms of diabetes: type 1 if the patient is young and not overweight, type 2 if the patient is overweight, or gestational diabetes if the patient is pregnant. Standard diabetes treatments (insulin for type 1 and gestational diabetes, and oral hypoglycemic agents for type 2) are often initiated before the doctor suspects a more unusual form of diabetes.

Pathophysiology

The recognised forms of MODY are all due to ineffective insulin production or release by pancreatic beta cells. Several of the defects are mutations of transcription factor genes. One form is due to mutations of the glucokinase gene. For each form of MODY, multiple specific mutations involving different amino acid substitutions have been discovered. In some cases, there are significant differences in the activity of the mutant gene product that contribute to variations in the clinical features of the diabetes (such as degree of insulin deficiency or age of onset).

Diagnosis

The following characteristics suggest the possibility of a diagnosis of MODY in hyperglycemic and diabetic patients:

• Mild to moderate hyperglycemia (typically 130–250 mg/dL, or 7–14 mmol/L) discovered before 25 years of age. However, anyone under 50 can develop MODY.
• A first-degree relative with a similar degree of diabetes.
• Absence of positive antibodies or other autoimmunity (e.g., thyroiditis) in patient and family. However, Urbanova et al. found that about one quarter of Central European MODY patients are positive for islet cell autoantibodies (GABA and IA2A). Their expression is transient but highly prevalent. The autoantibodies were found in patients with delayed diabetes onset, and in times of insufficient diabetes control. The islet cell autoantibodies are absent in MODY in at least some populations (Japanese, Britons).
• Persistence of a low insulin requirement (e.g., less than 0.5 u/kg/day) past the usual "honeymoon" period.
• Normal insulin levels (e.g. 2.6-24.9)
• Absence of obesity (although overweight or obese people can get MODY) or other problems associated with type 2 diabetes or metabolic syndrome (e.g., hypertension, hyperlipidemia, polycystic ovary syndrome).
• Insulin resistance very rarely happens.
• Cystic kidney disease in patient or close relatives.
• Non-transient neonatal diabetes, or apparent type 1 diabetes with onset before six months of age.
• Liver adenoma or hepatocellular carcinoma in MODY type 3
• Renal cysts, rudimentary or bicornuate uterus, vaginal aplasia, absence of the vas deferens, epidymal cysts in MODY type 5

The diagnosis of MODY is confirmed by specific gene testing available through commercial laboratories.

Classification

Heterozygous

MODY is inherited in an autosomal dominant fashion, and most patients therefore have other members of the family with diabetes; penetrance differs between the types (from 40% to 90%).

A newly discovered monogenetic form of diabetes is marked by a missense variant in the RyR2 gene. It has not yet received a MODY type.

Homozygous

By definition, the forms of MODY are autosomal dominant, requiring only one abnormal gene to produce the disease; the severity of the disease is moderated by the presence of a second, normal allele which presumably functions normally. However, conditions involving people carrying two abnormal alleles have been identified. Unsurprisingly, combined (homozygous) defects of these genes are much rarer and much more severe in their effects.

• MODY2: Homozygous glucokinase deficiency causes severe congenital insulin deficiency resulting in persistent neonatal diabetes mellitus. About 6 cases have been reported worldwide. All have required insulin treatment from shortly after birth. The condition does not seem to improve with age.
• MODY4: Homozygous IPF1 results in failure of the pancreas to form. Congenital absence of the pancreas, termed pancreatic agenesis, involves deficiency of both endocrine and exocrine functions of the pancreas.

Homozygous mutations in the other forms have not yet been described. Those mutations for which a homozygous form has not been described may be extremely rare, may result in clinical problems not yet recognized as connected to the monogenic disorder, or may be lethal for a fetus and not result in a viable child.

Treatment

In some forms of MODY, standard treatment is appropriate, though exceptions occur:

• In MODY2, oral agents are relatively ineffective, however most patients are managed conservatively through diet and exercise.
• In MODY1 and MODY3, sulfonylureas are usually very effective, delaying the need for insulin treatment.
• Sulfonylureas are effective in the KATP channel forms of neonatal-onset diabetes. The mouse model of MODY diabetes suggested that the reduced clearance of sulfonylureas stands behind their therapeutic success in human MODY patients, but Urbanova et al. found that human MODY patients respond differently to the mouse model and that there was no consistent decrease in the clearance of sulfonylureas in randomly selected HNF1A-MODY and HNF4A-MODY patients.

Chronic hyperglycemia due to any cause can eventually cause blood vessel damage and the microvascular complications of diabetes. The principal treatment goals for people with MODY — keeping the blood sugars as close to normal as possible ("good glycemic control"), while minimizing other vascular risk factors — are the same for all known forms of diabetes.

The tools for management are similar for all forms of diabetes: blood testing, changes in diet, physical exercise, oral hypoglycemic agents, and insulin injections. In many cases these goals can be achieved more easily with MODY than with ordinary types 1 and 2 diabetes. Some people with MODY may require insulin injections to achieve the same glycemic control that another person may attain with careful eating or an oral medication.

When oral hypoglycemic agents are used in MODY, the sulfonylureas remain the oral medication of first resort. When compared to patients with type 2 diabetes, MODY patients are often more sensitive to sulphonylureas, such that a lower dose should be used to initiate treatment to avoid hypoglycaemia. Patients with MODY less often suffer from obesity and insulin resistance than those with ordinary type 2 diabetes (for whom insulin sensitizers like metformin or the thiazolidinediones are often preferred over the sulfonylureas).

Epidemiology

According to data from Saxony, Germany, MODY was responsible for 2.4% of diabetes incidence in children younger than 15 years.

History

The term MODY dates back to 1964, when diabetes mellitus was considered to have two main forms: juvenile-onset and maturity-onset, which roughly corresponded to what we now call type 1 and type 2. MODY was originally applied to any child or young adult who had persistent, asymptomatic hyperglycemia without progression to diabetic ketosis or ketoacidosis. In retrospect we can now recognize that this category covered a heterogeneous collection of disorders which included cases of dominantly inherited diabetes (the topic of this article, still called MODY today), as well as cases of what we would now call type 2 diabetes occurring in childhood or adolescence, and a few even rarer types of hyperglycemia (e.g., mitochondrial diabetes or mutant insulin). Many of these patients were treated with sulfonylureas with varying degrees of success.

The current usage of the term MODY dates from a case report published in 1974.

Since the 1990s, as the understanding of the pathophysiology of diabetes has improved, the concept and usage of MODY have become refined and narrower. It is now used as a synonym for dominantly inherited, monogenic defects of insulin secretion occurring at any age, and no longer includes any forms of type 2 diabetes.

References

References

1. "Monogenic Diabetes (Neonatal Diabetes Mellitus & MODY)".
2. "Monogenic Diabetes (Neonatal Diabetes Mellitus & MODY)".
3. Chennai, India, Dr. V Mohan. (2020-07-15). "'Maturity Onset Diabetes of the Young (MODY) {{!}} Dr Mohans".
4. (2022-09-01). "Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY)". Journal of Diabetes Investigation.
5. (2020-11-04). "The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)". Clinical Diabetes and Endocrinology.
6. (2022-02-01). "Maturity-Onset Diabetes of the Young: Rapid Evidence Review". American Family Physician.
7. Urakami, Tatsuhiko. (2019-07-01). "Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.
8. (2019). "Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment". Diabetes Metabolic Syndrome & Obesity.
9. "MODY".
10. (2014). "Positivity for islet cell autoantibodies in patients with monogenic diabetes is associated with later diabetes onset and higher HbA1c level". Diabetic Medicine.
11. "Maturity Onset Diabetes". SparkPeople.
12. "MODY". Harvard.
13. (2010). "A missense TCF1 mutation in a patient with MODY-3 and liver adenomatosis". Clinics.
14. "Renal Cysts and Diabetes Syndrome".
15. (2014). "Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.". JAMA.
16. (2019). "Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry.". Acta Diabetologica.
17. (February 2001). "beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors". Diabetes.
18. (March 2005). "Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic β-cell function". Proc. Natl. Acad. Sci. U.S.A..
19. {{OMIM. 610508. MATURITY-ONSET DIABETES OF THE YOUNG, TYPE VII; MODY7
20. (January 2006). "Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction". Nat. Genet..
21. {{OMIM. 609812. MATURITY-ONSET DIABETES OF THE YOUNG, TYPE VIII, WITH EXOCRINE DYSFUNCTION; MODY8
22. (2024). "Whole-exome sequencing in familial type 2 diabetes identifies an atypical missense variant in the RyR2 gene.". Frontiers in Endocrinology.
23. (2008). "Genomics and clinical medicine". Oxford University Press US.
24. (2010). "Incidence of Childhood Diabetes in Children Aged Less than 15 Years and Its Clinical and Metabolic Characteristics at the Time of Diagnosis: Data from the Childhood Diabetes Registry of Saxony, Germany". Hormone Research in Paediatrics.
25. Tattersall RB. (1974). "Mild familial diabetes with dominant inheritance". Q J Med.
26. Tattersall, R. (1998). "Maturity-onset diabetes of the young: A clinical history". Diabetic Medicine.
27. American Diabetes, Association. (2009). "Diagnosis and Classification of Diabetes Mellitus". Diabetes Care.
28. Urbanova, J.. (2015). "Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/- Model". Current Pharmaceutical Design.